Zoledronic Acid (Zoledronate) for Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole (ZO-FAST Study): Final 60-month Results Ann Oncol. 2013 Feb24(2):398-405. doi: 10.1093/annonc/mds277. Epub 2012 Oct 9. Authors R Coleman 1 …
12/8/2011 · ZO-FAST: Immediate Zoledronic Acid Beats Delayed Tx in Early Breast Cancer. SAN ANTONIO – Immediate treatment with zoledronic acid in postmenopausal women with hormone receptor–positive breast cancer initiating letrozole therapy was associated with a 34% reduction in recurrence risk and 31% improvement in overall survival, compared with women of …
About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features Press Copyright Contact us Creators …
ZO-FAST Study of the Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Early Breast Cancer Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10), 12/12/2011 · The findings update those previously reported by Dr. de Boer of the Royal Melbourne Hospital and colleagues in the ZO-FAST (Zometa-Femara Adjuvant Synergy Trial), demonstrating that early zoledronic acid significantly improved bone mineral density and improved breast cancer disease-free survival.
studies(Z- FAST ZO-FAST E- ZO-FAST )andinthesim-ilarly-designedN03CCstudy.15 Interim (<36months fol-low-up) results from the former 3 studies indicate that upfront rather than delayed-start zoledronic acid is signifi-cantly more effective in preventing bone loss.2,3,13,14 This articlereportsthefinal,5-yearresultsoftheZ-FASTstudy. MATERIALS AND METHODS, Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole ( ZO-FAST study): final 60-month results. Research output: Contribution to journal › Article › peer-review, Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST Cancer Research, 2009 A..Several large, randomized, multicenter trials are underway to determine whether upfront or delayed ZA therapy can decrease BMD losses in patients undergoing treatment with the antiaromatase agent letrozole (Z- FAST ZO-FAST , and E- ZO-FAST ), and early results from the Zometa-Femara adjuvant synergy trial (Z- FAST ) trial indicate a significant ...Upfront zoledronic acid seems to be the preferred treatment strategy versus delayed administration, as it significantly and progressively increases BMD in postmenopausal women with early BC receiving letrozole for 5 years, and long-term coadministration of letrozole and zoledronic acid is well toler …
